Levokabastin

Levokabastin
(IUPAC) ime
	(3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid
Klinički podaci
Identifikatori
CAS broj	79516-68-0
ATC kod	R01AC02 S01GX02
PubChem	54385
DrugBank	APRD01069
ChemSpider	16736421
UNII	H68BP06S81
KEGG	D08117
ChEMBL	CHEMBL1201312
Hemijski podaci
Formula	C26H29FN2O2
Mol. masa	420.519 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)/t19-,23-,25-,26-/m1/s1 ; Key: ZCGOMHNNNFPNMX-KYTRFIICSA-N
Farmakokinetički podaci
Poluvreme eliminacije	3
Farmakoinformacioni podaci
Trudnoća	B3(AU) C(US)
Pravni status	℞ Prescription only
Način primene	Oftalmično, intranazalno

Levokabastin je selektivni antagonist H₁ receptora druge generacije koji je razvila kompanija Jansen Farmaceutikal 1979. On se koristi za lečenje alergijskog konjunktivitisa.^[7]

Pored antihistaminskog dejstva, levokabastin takođe deluje kao potentan i selektivan antagonist neurotenzinskog receptora NTS₂, i bio je prvi lek koji je korišten za karakterisanje raznih neurotenzinskih podtipova.^[8]^[9]^[10]^[11]^[12]^[13]^[14]

Literatura[uredi - уреди | uredi izvor]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3. edit
↑ Joanne Wixon, Douglas Kell (2000). "Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG". Yeast 17 (1): 48–55. doi:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777. edit
↑ "RxMed: Pharmaceutical Information - LIVOSTIN NASAL SPRAY". http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20L)/LIVOSTIN%20NASAL%20SPRAY.html. Pristupljeno 13 November 2005.
↑ Pipkorn U, Bende M, Hedner J, Hedner T., A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis. Allergy. 1985 Oct;40(7):491-6.
↑ Schotte A, Leysen JE, Laduron PM (August 1986). "Evidence for a displaceable non-specific [3H]neurotensin binding site in rat brain". Naunyn-Schmiedeberg's Archives of Pharmacology 333 (4): 400–5. PMID 3022160. doi:10.1007/BF00500016.
↑ Kitabgi P, Rostène W, Dussaillant M, Schotte A, Laduron PM, Vincent JP (August 1987). "Two populations of neurotensin binding sites in murine brain: discrimination by the antihistamine levocabastine reveals markedly different radioautographic distribution". European Journal of Pharmacology 140 (3): 285–93. PMID 2888670. doi:10.1016/0014-2999(87)90285-8.
↑ Chalon P, Vita N, Kaghad M, Guillemot M, Bonnin J, Delpech B, Le Fur G, Ferrara P, Caput D (May 1996). "Molecular cloning of a levocabastine-sensitive neurotensin binding site". FEBS Letters 386 (2-3): 91–4. PMID 8647296. doi:10.1016/0014-5793(96)00397-3.
↑ Mazella J, Botto JM, Guillemare E, Coppola T, Sarret P, Vincent JP (September 1996). "Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain". The Journal of Neuroscience : the Official Journal of the Society for Neuroscience 16 (18): 5613–20. PMID 8795617.
↑ Sarret P, Esdaile MJ, Perron A, Martinez J, Stroh T, Beaudet A (September 2005). "Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors". The Journal of Neuroscience : the Official Journal of the Society for Neuroscience 25 (36): 8188–96. PMID 16148226. doi:10.1523/JNEUROSCI.0810-05.2005.
↑ Bredeloux P, Costentin J, Dubuc I (December 2006). "Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice". Behavioural Brain Research 175 (2): 399–407. PMID 17074405. doi:10.1016/j.bbr.2006.09.016.
↑ Yamauchi R, Wada E, Kamichi S, Yamada D, Maeno H, Delawary M, Nakazawa T, Yamamoto T, Wada K (September 2007). "Neurotensin type 2 receptor is involved in fear memory in mice". Journal of Neurochemistry 102 (5): 1669–76. PMID 17697051. doi:10.1111/j.1471-4159.2007.04805.x.

Spoljašnje veze[uredi - уреди | uredi izvor]

	Portal Medicina
	Portal Hemija

Novartis Pharmaceuticals (March 2002). "LIVOSTIN" (PDF). http://www.pharma.us.novartis.com/product/pi/pdf/livostin.pdf. Pristupljeno 20. 08. 2006..

Šablon:Neuropeptidni ligandi

Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3. edit

[4] Joanne Wixon, Douglas Kell (2000). "Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG". Yeast 17 (1): 48–55. doi:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777. edit

[6] "RxMed: Pharmaceutical Information - LIVOSTIN NASAL SPRAY". http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20L)/LIVOSTIN%20NASAL%20SPRAY.html. Pristupljeno 13 November 2005.

[7] Pipkorn U, Bende M, Hedner J, Hedner T., A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis. Allergy. 1985 Oct;40(7):491-6.

[pmid3022160-8] Schotte A, Leysen JE, Laduron PM (August 1986). "Evidence for a displaceable non-specific [3H]neurotensin binding site in rat brain". Naunyn-Schmiedeberg's Archives of Pharmacology 333 (4): 400–5. PMID 3022160. doi:10.1007/BF00500016.

[pmid2888670-9] Kitabgi P, Rostène W, Dussaillant M, Schotte A, Laduron PM, Vincent JP (August 1987). "Two populations of neurotensin binding sites in murine brain: discrimination by the antihistamine levocabastine reveals markedly different radioautographic distribution". European Journal of Pharmacology 140 (3): 285–93. PMID 2888670. doi:10.1016/0014-2999(87)90285-8.

[pmid8647296-10] Chalon P, Vita N, Kaghad M, Guillemot M, Bonnin J, Delpech B, Le Fur G, Ferrara P, Caput D (May 1996). "Molecular cloning of a levocabastine-sensitive neurotensin binding site". FEBS Letters 386 (2-3): 91–4. PMID 8647296. doi:10.1016/0014-5793(96)00397-3.

[pmid8795617-11] Mazella J, Botto JM, Guillemare E, Coppola T, Sarret P, Vincent JP (September 1996). "Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain". The Journal of Neuroscience : the Official Journal of the Society for Neuroscience 16 (18): 5613–20. PMID 8795617.

[pmid16148226-12] Sarret P, Esdaile MJ, Perron A, Martinez J, Stroh T, Beaudet A (September 2005). "Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors". The Journal of Neuroscience : the Official Journal of the Society for Neuroscience 25 (36): 8188–96. PMID 16148226. doi:10.1523/JNEUROSCI.0810-05.2005.

[pmid17074405-13] Bredeloux P, Costentin J, Dubuc I (December 2006). "Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice". Behavioural Brain Research 175 (2): 399–407. PMID 17074405. doi:10.1016/j.bbr.2006.09.016.

[pmid17697051-14] Yamauchi R, Wada E, Kamichi S, Yamada D, Maeno H, Delawary M, Nakazawa T, Yamamoto T, Wada K (September 2007). "Neurotensin type 2 receptor is involved in fear memory in mice". Journal of Neurochemistry 102 (5): 1669–76. PMID 17697051. doi:10.1111/j.1471-4159.2007.04805.x.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

Levokabastin

Literatura[uredi - уреди | uredi izvor]

Spoljašnje veze[uredi - уреди | uredi izvor]

Navigacijski meni

Traži-Тражи